Search
Upstream Bio Inc
UPBAdd to Watchlist
4.835USD
-0.205-4.07%
Market hours 10/05, 14:11（ET）
263.12MMarket Cap
LossP/E TTM
Upstream Bio Inc (UPB) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Upstream Bio Inc in the past month.
Buy
1 Strong Buy
5 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
34.000USD+574.60%
UPB Analyst Recommendation Trends
In the current month, UPB has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. UPB average Analyst price target in the last month is 34.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
1
1
1
1
1
5
5
6
6
6
6
7
7
2
2
2
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
9
8
8
8
8
8
UPB Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, UPB EPS is projected to reach -0.729 in FY2026Q3, following reported EPS of -0.728 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.70
-0.77
-0.76
-0.73
-0.73
Actual
-2.66
-0.75
-0.73
--
--
Surprise
-281.20%
+3.39%
+4.41%
--
--
FAQs
What is Upstream Bio Inc's expected revenue for the next quarter?
Upstream Bio Inc's expected revenue is 480.14K.
What is Upstream Bio Inc's price target?
Analysts forecast that Upstream Bio Inc's price target is USD 34.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 15.00.
How have Upstream Bio IncUPB's recent earnings per share performed?
The market expectation was USD -0.73, while Upstream Bio IncUPB's earnings per share (EPS) for the previous quarter was USD -0.75. EPS for the next quarter is expected at USD -0.73.
What is the analyst rating for Upstream Bio Inc?
Based on the ratings of Upstream Bio Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.